U.S. Markets closed

Sunesis Pharmaceuticals, Inc. (SNSS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.32+1.04 (+24.30%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.28
Open4.67
Bid0.00 x 1400
Ask0.00 x 3200
Day's Range4.70 - 7.09
52 Week Range3.92 - 35.00
Volume70,241,798
Avg. Volume907,709
Market Cap96.335M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Sunesis Pharma Climbs After Viracta Poised To Nab US Patent For Nanatinostat/Valganciclovir Regime

    Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) merger partner, Viracta Therapeutics Inc announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," related to the use of Viracta's oral combination product candidate of nanatinostat and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial to treat Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will provide protection into at least 2040. In November last year, Sunesis Pharmaceuticals announced to merge with Viracta Therapeutics in an all-stock deal. Price Action: SNSS gained 5.5% at $3.49 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaAddex Therapeutics' GABAB PAM Candidate Shows Potential For Alcohol Use DisorderWindtree Therapeutics' AEROSURF Drug Delivery Device Secures US Patent© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is Sunesis Pharmaceuticals (SNSS) A Good Stock To Buy Now?
    Insider Monkey

    Is Sunesis Pharmaceuticals (SNSS) A Good Stock To Buy Now?

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]

  • Implied Volatility Surging for Sunesis Pharmaceuticals (SNSS) Stock Options
    Zacks

    Implied Volatility Surging for Sunesis Pharmaceuticals (SNSS) Stock Options

    Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.